Oncology Operating Income from 2010 to 2026

TOI Stock

USD 2.56 0.04 1.54%

Oncology Institute's Operating Income is decreasing with slightly volatile movements from year to year. Operating Income is predicted to flatten to about -56.8 M. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Oncology Institute generates from its operations. View All Fundamentals

Operating Income

First Reported

2018-12-31

Previous Quarter

-11.2 M

Current Value

-8.1 M

Quarterly Volatility

10.5 M

Covid

Interest Hikes

Check Oncology Institute financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncology Institute's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 4.3 M or Interest Expense of 9.1 M, as well as many indicators such as Price To Sales Ratio of 0.0644, Dividend Yield of 0.0105 or PTB Ratio of 9.87. Oncology financial statements analysis is a perfect complement when working with Oncology Institute Valuation or Volatility modules.

Build AI portfolio with Oncology Stock

Check out the analysis of Oncology Institute Correlation against competitors.

For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.

The Operating Income trend for Oncology Institute offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Oncology Institute is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Oncology Institute's Operating Income Growth Pattern

Below is the plot of the Operating Income of Oncology Institute over the last few years. Operating Income is the amount of profit realized from Oncology Institute operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Oncology Institute is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Oncology Institute's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncology Institute's overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Oncology Operating Income Regression Statistics

	Arithmetic Mean	(20,211,616)
	Geometric Mean	11,744,010
	Coefficient Of Variation	(165.28)
	Mean Deviation	29,952,119
	Median	4,789,544
	Standard Deviation	33,406,458
	Sample Variance	1116T
	Range	86.7M
	R-Value	(0.83)
	Mean Square Error	373.5T
	R-Squared	0.69
	Significance	0.00004
	Slope	(5,480,078)
	Total Sum of Squares	17855.9T

Oncology Operating Income History

	2026	-56.8 M
	2025	-54.1 M
	2024	-60.1 M
	2023	-77 M
	2022	-82 M
	2021	-45.9 M
	2020	-8.2 M

Other Fundumenentals of Oncology Institute

Non Operating Income Net Other

Oncology Institute Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Short Long Term Debt	Short Term Debt	Capital Surpluse
Total Assets		0.32	0.9	0.5	-0.75	0.61	0.85	0.07	0.92	0.98	0.97	-0.92	0.96	-0.82	0.89	0.9	-0.28	0.95	-0.97	-0.04	0.74
Total Stockholder Equity	0.32		0.27	-0.32	0.37	-0.42	-0.15	0.81	-0.04	0.37	0.25	-0.16	0.4	0.25	0.01	-0.1	-0.88	0.06	-0.13	-0.6	-0.3
Net Tangible Assets	0.9	0.27		0.19	-0.7	0.64	0.7	0.18	0.82	0.85	0.95	-0.93	0.95	-0.77	0.8	0.78	-0.24	0.91	-0.94	-0.32	0.61
Net Debt	0.5	-0.32	0.19		-0.66	0.43	0.75	-0.64	0.63	0.55	0.39	-0.47	0.29	-0.61	0.51	0.75	0.31	0.53	-0.5	0.79	0.77
Retained Earnings	-0.75	0.37	-0.7	-0.66		-0.9	-0.92	0.48	-0.92	-0.69	-0.79	0.78	-0.67	0.97	-0.89	-0.93	-0.28	-0.89	0.87	-0.33	-0.87
Accounts Payable	0.61	-0.42	0.64	0.43	-0.9		0.85	-0.46	0.85	0.53	0.69	-0.66	0.53	-0.9	0.81	0.75	0.36	0.81	-0.73	0.29	0.82
Net Receivables	0.85	-0.15	0.7	0.75	-0.92	0.85		-0.43	0.98	0.83	0.83	-0.83	0.72	-0.92	0.88	0.94	0.12	0.93	-0.88	0.43	0.93
Good Will	0.07	0.81	0.18	-0.64	0.48	-0.46	-0.43		-0.29	0.05	0.03	0.06	0.18	0.31	-0.15	-0.31	-0.57	-0.15	0.06	-0.87	-0.48
Total Liab	0.92	-0.04	0.82	0.63	-0.92	0.85	0.98	-0.29		0.88	0.92	-0.89	0.83	-0.94	0.94	0.95	0.0	0.98	-0.95	0.25	0.88
Net Invested Capital	0.98	0.37	0.85	0.55	-0.69	0.53	0.83	0.05	0.88		0.93	-0.93	0.93	-0.75	0.81	0.88	-0.32	0.91	-0.93	0.03	0.71
Total Current Assets	0.97	0.25	0.95	0.39	-0.79	0.69	0.83	0.03	0.92	0.93		-0.93	0.98	-0.84	0.92	0.88	-0.28	0.97	-0.98	-0.12	0.72
Capital Stock	-0.92	-0.16	-0.93	-0.47	0.78	-0.66	-0.83	0.06	-0.89	-0.93	-0.93		-0.91	0.81	-0.77	-0.89	0.12	-0.94	0.96	0.01	-0.75
Net Working Capital	0.96	0.4	0.95	0.29	-0.67	0.53	0.72	0.18	0.83	0.93	0.98	-0.91		-0.73	0.83	0.8	-0.42	0.91	-0.94	-0.26	0.59
Intangible Assets	-0.82	0.25	-0.77	-0.61	0.97	-0.9	-0.92	0.31	-0.94	-0.75	-0.84	0.81	-0.73		-0.93	-0.94	-0.25	-0.93	0.9	-0.23	-0.9
Common Stock	0.89	0.01	0.8	0.51	-0.89	0.81	0.88	-0.15	0.94	0.81	0.92	-0.77	0.83	-0.93		0.89	-0.07	0.93	-0.92	0.08	0.78
Property Plant Equipment	0.9	-0.1	0.78	0.75	-0.93	0.75	0.94	-0.31	0.95	0.88	0.88	-0.89	0.8	-0.94	0.89		0.11	0.94	-0.94	0.29	0.91
Current Deferred Revenue	-0.28	-0.88	-0.24	0.31	-0.28	0.36	0.12	-0.57	0.0	-0.32	-0.28	0.12	-0.42	-0.25	-0.07	0.11		-0.07	0.13	0.54	0.34
Long Term Debt	0.95	0.06	0.91	0.53	-0.89	0.81	0.93	-0.15	0.98	0.91	0.97	-0.94	0.91	-0.93	0.93	0.94	-0.07		-0.99	0.08	0.84
Short Long Term Debt	-0.97	-0.13	-0.94	-0.5	0.87	-0.73	-0.88	0.06	-0.95	-0.93	-0.98	0.96	-0.94	0.9	-0.92	-0.94	0.13	-0.99		0.01	-0.78
Short Term Debt	-0.04	-0.6	-0.32	0.79	-0.33	0.29	0.43	-0.87	0.25	0.03	-0.12	0.01	-0.26	-0.23	0.08	0.29	0.54	0.08	0.01		0.5
Capital Surpluse	0.74	-0.3	0.61	0.77	-0.87	0.82	0.93	-0.48	0.88	0.71	0.72	-0.75	0.59	-0.9	0.78	0.91	0.34	0.84	-0.78	0.5

Click cells to compare fundamentals

About Oncology Institute Financial Statements

Investors use fundamental indicators, such as Oncology Institute's Operating Income, to determine how well the company is positioned to perform in the future. Although Oncology Institute's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.

	Last Reported	Projected for Next Year
Operating Income	-54.1 M	-56.8 M
Non Operating Income Net Other	98.8 M	103.8 M

Currently Active Assets on Macroaxis

FSLY	Fastly Class A
MOB	Mobilicom Limited American
CMG	Chipotle Mexican Grill
CSAN	Cosan SA ADR
RKT	Rocket Companies

When determining whether Oncology Institute offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncology Institute's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncology Institute Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncology Institute Stock:

How To Invest In Oncology

Details

Is Oncology Stock a good investment?

Details

What is Oncology Institute's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out the analysis of Oncology Institute Correlation against competitors.

For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.

You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Is there potential for Health Care Equipment & Supplies market expansion? Will Oncology introduce new products? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.67)

Revenue Per Share

5.279

Quarterly Revenue Growth

0.215

Return On Assets

(0.17)

Return On Equity

(6.52)

Investors evaluate Oncology Institute using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Oncology Institute's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Oncology Institute's market price to deviate significantly from intrinsic value.

Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Oncology Institute's market price signifies the transaction level at which participants voluntarily complete trades.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Oncology Operating Income from 2010 to 2026

Latest Oncology Institute's Operating Income Growth Pattern

Oncology Operating Income Regression Statistics

Oncology Operating Income History

Other Fundumenentals of Oncology Institute

Oncology Institute Operating Income component correlations

About Oncology Institute Financial Statements

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY